Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1221

1.

Twin study shows association between monocyte chemoattractant protein-1 and kynurenic acid in cerebrospinal fluid.

Johansson V, Erhardt S, Engberg G, Kegel M, Bhat M, Schwieler L, Blennow K, Zetterberg H, Cannon TD, Wetterberg L, Hultman CM, Landén M.

Eur Arch Psychiatry Clin Neurosci. 2019 Jul 13. doi: 10.1007/s00406-019-01042-9. [Epub ahead of print]

PMID:
31302732
2.

Characterization of Cerebrospinal Fluid BACE1 Species.

Lopez-Font I, Boix CP, Zetterberg H, Blennow K, Sáez-Valero J.

Mol Neurobiol. 2019 Jul 9. doi: 10.1007/s12035-019-01677-8. [Epub ahead of print]

PMID:
31290061
3.

Comparison of different MRI-based morphometric estimates for defining neurodegeneration across the Alzheimer's disease continuum.

Allison SL, Koscik RL, Cary RP, Jonaitis EM, Rowley HA, Chin NA, Zetterberg H, Blennow K, Carlsson CM, Asthana S, Bendlin BB, Johnson SC.

Neuroimage Clin. 2019 Jun 10;23:101895. doi: 10.1016/j.nicl.2019.101895. [Epub ahead of print]

4.

Correlations between serum and CSF pNfH levels in ALS, FTD and controls: a comparison of three analytical approaches.

Wilke C, Pujol-Calderón F, Barro C, Stransky E, Blennow K, Michalak Z, Deuschle C, Jeromin A, Zetterberg H, Schüle R, Höglund K, Kuhle J, Synofzik M.

Clin Chem Lab Med. 2019 May 9. pii: /j/cclm.ahead-of-print/cclm-2019-0015/cclm-2019-0015.xml. doi: 10.1515/cclm-2019-0015. [Epub ahead of print]

PMID:
31251725
5.

Sex Difference in CHI3L1 Expression Levels in Human Brain Aging and in Alzheimer's Disease.

Sanfilippo C, Castrogiovanni P, Imbesi R, Kazakowa M, Musumeci G, Blennow K, Zetterberg H, Di Rosa M.

Brain Res. 2019 Jun 24:146305. doi: 10.1016/j.brainres.2019.146305. [Epub ahead of print]

PMID:
31247206
6.

Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease-Related β-Amyloid Status.

Palmqvist S, Janelidze S, Stomrud E, Zetterberg H, Karl J, Zink K, Bittner T, Mattsson N, Eichenlaub U, Blennow K, Hansson O.

JAMA Neurol. 2019 Jun 24. doi: 10.1001/jamaneurol.2019.1632. [Epub ahead of print]

7.

Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis.

Bridel C, van Wieringen WN, Zetterberg H, Tijms BM, Teunissen CE; and the NFL Group, Alvarez-Cermeño JC, Andreasson U, Axelsson M, Bäckström DC, Bartos A, Bjerke M, Blennow K, Boxer A, Brundin L, Burman J, Christensen T, Fialová L, Forsgren L, Frederiksen JL, Gisslén M, Gray E, Gunnarsson M, Hall S, Hansson O, Herbert MK, Jakobsson J, Jessen-Krut J, Janelidze S, Johannsson G, Jonsson M, Kappos L, Khademi M, Khalil M, Kuhle J, Landén M, Leinonen V, Logroscino G, Lu CH, Lycke J, Magdalinou NK, Malaspina A, Mattsson N, Meeter LH, Mehta SR, Modvig S, Olsson T, Paterson RW, Pérez-Santiago J, Piehl F, Pijnenburg YAL, Pyykkö OT, Ragnarsson O, Rojas JC, Romme Christensen J, Sandberg L, Scherling CS, Schott JM, Sellebjerg FT, Simone IL, Skillbäck T, Stilund M, Sundström P, Svenningsson A, Tortelli R, Tortorella C, Trentini A, Troiano M, Turner MR, van Swieten JC, Vågberg M, Verbeek MM, Villar LM, Visser PJ, Wallin A, Weiss A, Wikkelsø C, Wild EJ.

JAMA Neurol. 2019 Jun 17. doi: 10.1001/jamaneurol.2019.1534. [Epub ahead of print]

PMID:
31206160
8.

Plasma and CSF neurofilament light: Relation to longitudinal neuroimaging and cognitive measures.

Mielke MM, Syrjanen JA, Blennow K, Zetterberg H, Vemuri P, Skoog I, Machulda MM, Kremers WK, Knopman DS, Jack C Jr, Petersen RC, Kern S.

Neurology. 2019 Jul 16;93(3):e252-e260. doi: 10.1212/WNL.0000000000007767. Epub 2019 Jun 10.

PMID:
31182505
9.

Serum tau concentration after diving - an observational pilot study.

Rosén A, Oscarsson N, Kvarnström A, Gennser M, Sandström G, Blennow K, Seeman-Lodding H, Zetterberg H.

Diving Hyperb Med. 2019 Jun 30;49(2):88-95. doi: 10.28920/dhm49.2.88-95.

PMID:
31177514
10.

CSF biomarkers distinguish idiopathic normal pressure hydrocephalus from its mimics.

Jeppsson A, Wikkelsö C, Blennow K, Zetterberg H, Constantinescu R, Remes AM, Herukka SK, Rauramaa T, Nagga K, Leinonen V, Tullberg M.

J Neurol Neurosurg Psychiatry. 2019 Jun 5. pii: jnnp-2019-320826. doi: 10.1136/jnnp-2019-320826. [Epub ahead of print]

11.

Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype.

Vermunt L, Sikkes SAM, van den Hout A, Handels R, Bos I, van der Flier WM, Kern S, Ousset PJ, Maruff P, Skoog I, Verhey FRJ, Freund-Levi Y, Tsolaki M, Wallin ÅK, Olde Rikkert M, Soininen H, Spiru L, Zetterberg H, Blennow K, Scheltens P, Muniz-Terrera G, Visser PJ; Alzheimer Disease Neuroimaging Initiative; AIBL Research Group; ICTUS/DSA study groups.

Alzheimers Dement. 2019 Jun 1. pii: S1552-5260(19)30084-6. doi: 10.1016/j.jalz.2019.04.001. [Epub ahead of print]

PMID:
31164314
12.

Cerebrospinal Fluid Concentrations of Extracellular Matrix Proteins in Alzheimer's Disease.

Minta K, Portelius E, Janelidze S, Hansson O, Zetterberg H, Blennow K, Andreasson U.

J Alzheimers Dis. 2019;69(4):1213-1220. doi: 10.3233/JAD-190187.

PMID:
31156172
13.

Serum Neurofilament Light Chain Concentration Correlates with Infarct Volume but Not Prognosis in Acute Ischemic Stroke.

Onatsu J, Vanninen R, Jäkälä P, Mustonen P, Pulkki K, Korhonen M, Hedman M, Zetterberg H, Blennow K, Höglund K, Herukka SK, Taina M.

J Stroke Cerebrovasc Dis. 2019 May 28. pii: S1052-3057(19)30228-9. doi: 10.1016/j.jstrokecerebrovasdis.2019.05.008. [Epub ahead of print]

PMID:
31151840
14.

CSF placental growth factor - a novel candidate biomarker of frontotemporal dementia.

Hansson O, Santillo AF, Meeter LH, Nilsson K, Landqvist Waldö M, Nilsson C, Blennow K, van Swieten JC, Janelidze S.

Ann Clin Transl Neurol. 2019 Mar 29;6(5):863-872. doi: 10.1002/acn3.763. eCollection 2019 May.

15.

A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity.

van der Lee SJ, Conway OJ, Jansen I, Carrasquillo MM, Kleineidam L, van den Akker E, Hernández I, van Eijk KR, Stringa N, Chen JA, Zettergren A, Andlauer TFM, Diez-Fairen M, Simon-Sanchez J, Lleó A, Zetterberg H, Nygaard M, Blauwendraat C, Savage JE, Mengel-From J, Moreno-Grau S, Wagner M, Fortea J, Keogh MJ, Blennow K, Skoog I, Friese MA, Pletnikova O, Zulaica M, Lage C, de Rojas I, Riedel-Heller S, Illán-Gala I, Wei W, Jeune B, Orellana A, Then Bergh F, Wang X, Hulsman M, Beker N, Tesi N, Morris CM, Indakoetxea B, Collij LE, Scherer M, Morenas-Rodríguez E, Ironside JW, van Berckel BNM, Alcolea D, Wiendl H, Strickland SL, Pastor P, Rodríguez Rodríguez E; DESGESCO (Dementia Genetics Spanish Consortium), EADB (Alzheimer Disease European DNA biobank); EADB (Alzheimer Disease European DNA biobank); IFGC (International FTD-Genomics Consortium), IPDGC (The International Parkinson Disease Genomics Consortium); IPDGC (The International Parkinson Disease Genomics Consortium); RiMod-FTD (Risk and Modifying factors in Fronto-Temporal Dementia); Netherlands Brain Bank (NBB), Boeve BF, Petersen RC, Ferman TJ, van Gerpen JA, Reinders MJT, Uitti RJ, Tárraga L, Maier W, Dols-Icardo O, Kawalia A, Dalmasso MC, Boada M, Zettl UK, van Schoor NM, Beekman M, Allen M, Masliah E, de Munain AL, Pantelyat A, Wszolek ZK, Ross OA, Dickson DW, Graff-Radford NR, Knopman D, Rademakers R, Lemstra AW, Pijnenburg YAL, Scheltens P, Gasser T, Chinnery PF, Hemmer B, Huisman MA, Troncoso J, Moreno F, Nohr EA, Sørensen TIA, Heutink P, Sánchez-Juan P, Posthuma D; GIFT (Genetic Investigation in Frontotemporal Dementia and Alzheimer’s Disease) Study Group, Clarimón J, Christensen K, Ertekin-Taner N, Scholz SW, Ramirez A, Ruiz A, Slagboom E, van der Flier WM, Holstege H.

Acta Neuropathol. 2019 May 27. doi: 10.1007/s00401-019-02026-8. [Epub ahead of print]

PMID:
31131421
16.

Cerebrospinal fluid neurofilament light chain tracks cognitive impairment in multiple sclerosis.

Gaetani L, Salvadori N, Lisetti V, Eusebi P, Mancini A, Gentili L, Borrelli A, Portaccio E, Sarchielli P, Blennow K, Zetterberg H, Parnetti L, Calabresi P, Di Filippo M.

J Neurol. 2019 May 25. doi: 10.1007/s00415-019-09398-7. [Epub ahead of print]

PMID:
31129709
17.

Elecsys® Total-Tau and Phospho-Tau (181P) CSF assays: Analytical performance of the novel, fully automated immunoassays for quantification of tau proteins in human cerebrospinal fluid.

Lifke V, Kollmorgen G, Manuilova E, Oelschlaegel T, Hillringhaus L, Widmann M, von Arnim CAF, Otto M, Christenson RH, Powers JL, Shaw LM, Hansson O, Doecke JD, Li QX, Teunissen C, Tumani H, Blennow K.

Clin Biochem. 2019 May 23. pii: S0009-9120(19)30492-8. doi: 10.1016/j.clinbiochem.2019.05.005. [Epub ahead of print]

18.

Method comparison study of the Elecsys® β-Amyloid (1-42) CSF assay versus comparator assays and LC-MS/MS.

Shaw LM, Hansson O, Manuilova E, Masters CL, Doecke JD, Li QX, Rutz S, Widmann M, Leinenbach A, Blennow K.

Clin Biochem. 2019 May 23. pii: S0009-9120(19)30488-6. doi: 10.1016/j.clinbiochem.2019.05.006. [Epub ahead of print]

19.

Longstanding psychological stress in relation to biomarkers of neuronal dysfunction in cerebrospinal fluid: a 25-year follow-up study in women.

Johansson L, Sacuiu S, Kern S, Guo X, Zetterberg H, Blennow K, Zettergren A, Skoog I.

Neurobiol Aging. 2019 Feb 27;80:111-115. doi: 10.1016/j.neurobiolaging.2019.02.013. [Epub ahead of print]

PMID:
31128566
20.

NFL is a marker of treatment response in children with SMA treated with nusinersen.

Olsson B, Alberg L, Cullen NC, Michael E, Wahlgren L, Kroksmark AK, Rostasy K, Blennow K, Zetterberg H, Tulinius M.

J Neurol. 2019 May 23. doi: 10.1007/s00415-019-09389-8. [Epub ahead of print]

PMID:
31123861
21.

Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease.

Vergallo A, Mégret L, Lista S, Cavedo E, Zetterberg H, Blennow K, Vanmechelen E, De Vos A, Habert MO, Potier MC, Dubois B, Neri C, Hampel H; INSIGHT-preAD study group; Alzheimer Precision Medicine Initiative (APMI).

Alzheimers Dement. 2019 Jun;15(6):764-775. doi: 10.1016/j.jalz.2019.03.009. Epub 2019 May 18.

PMID:
31113759
22.

Erlangen Score Predicts Cognitive and Neuroimaging Progression in Mild Cognitive Impairment Stage of Alzheimer's Disease.

Skillbäck T, Kornhuber J, Blennow K, Zetterberg H, Lewczuk P; Alzheimer’s Disease Neuroimaging Initiative.

J Alzheimers Dis. 2019;69(2):551-559. doi: 10.3233/JAD-190067.

PMID:
31104027
23.

Reduced vascular endothelial growth factor levels in the cerebrospinal fluid in patients with treatment resistant major depression and the effects of electroconvulsive therapy-A pilot study.

Kranaster L, Blennow K, Zetterberg H, Sartorius A.

J Affect Disord. 2019 Jun 15;253:449-453. doi: 10.1016/j.jad.2019.04.080. Epub 2019 Apr 18.

PMID:
31103810
24.

CSF neurogranin as a neuronal damage marker in CJD: a comparative study with AD.

Blennow K, Diaz-Lucena D, Zetterberg H, Villar-Pique A, Karch A, Vidal E, Hermann P, Schmitz M, Ferrer Abizanda I, Zerr I, Llorens F.

J Neurol Neurosurg Psychiatry. 2019 Aug;90(8):846-853. doi: 10.1136/jnnp-2018-320155. Epub 2019 May 16.

PMID:
31097472
25.

Head trauma in sports and risk for dementia.

Winblad B, Ankarcrona M, Johansson G, Novak P, Peter Thelin E, Zetterberg H, Blennow K.

J Intern Med. 2019 Jun;285(6):591-593. doi: 10.1111/joim.12918. Epub 2019 May 15. No abstract available.

PMID:
31090251
26.

Cerebrospinal fluid biomarkers in patients with neurological symptoms but without neurological diseases.

Constantinescu R, Mahamud U, Constantinescu C, Eriksson B, Novakova L, Olsson B, Rosengren L, Blennow K, Axelsson M.

Acta Neurol Scand. 2019 May 14. doi: 10.1111/ane.13118. [Epub ahead of print]

PMID:
31087810
27.

Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort.

Kim M, Snowden S, Suvitaival T, Ali A, Merkler DJ, Ahmad T, Westwood S, Baird A, Proitsi P, Nevado-Holgado A, Hye A, Bos I, Vos S, Vandenberghe R, Teunissen C, Ten Kate M, Scheltens P, Gabel S, Meersmans K, Blin O, Richardson J, De Roeck E, Sleegers K, Bordet R, Rami L, Kettunen P, Tsolaki M, Verhey F, Sala I, Lléo A, Peyratout G, Tainta M, Johannsen P, Freund-Levi Y, Frölich L, Dobricic V, Engelborghs S, Frisoni GB, Molinuevo JL, Wallin A, Popp J, Martinez-Lage P, Bertram L, Barkhof F, Ashton N, Blennow K, Zetterberg H, Streffer J, Visser PJ, Lovestone S, Legido-Quigley C.

Alzheimers Dement. 2019 Jun;15(6):817-827. doi: 10.1016/j.jalz.2019.03.004. Epub 2019 May 8.

28.

A Serum Protein Biomarker Panel Improves Outcome Prediction in Human Traumatic Brain Injury.

Thelin E, Al Nimer F, Frostell A, Zetterberg H, Blennow K, Nyström H, Svensson M, Bellander BM, Piehl F, Nelson DW.

J Neurotrauma. 2019 Jun 19. doi: 10.1089/neu.2019.6375. [Epub ahead of print]

PMID:
31072225
29.

Cerebrospinal fluid neurofilament light and tau protein as mortality biomarkers in parkinsonism.

Constantinescu R, Rosengren L, Eriksson B, Blennow K, Axelsson M.

Acta Neurol Scand. 2019 Aug;140(2):147-156. doi: 10.1111/ane.13116. Epub 2019 May 20.

PMID:
31070772
30.

Plasma Biomarkers of AD Emerging as Essential Tools for Drug Development: An EU/US CTAD Task Force Report.

Bateman RJ, Blennow K, Doody R, Hendrix S, Lovestone S, Salloway S, Schindler R, Weiner M, Zetterberg H, Aisen P, Vellas B.

J Prev Alzheimers Dis. 2019;6(3):169-173. doi: 10.14283/jpad.2019.21.

PMID:
31062827
31.

Anti-Tau Trials for Alzheimer's Disease: A Report from the EU/US/CTAD Task Force.

Cummings J, Blennow K, Johnson K, Keeley M, Bateman RJ, Molinuevo JL, Touchon J, Aisen P, Vellas B.

J Prev Alzheimers Dis. 2019;6(3):157-163. doi: 10.14283/jpad.2019.14.

PMID:
31062825
32.

Association of Blood and Cerebrospinal Fluid Tau Level and Other Biomarkers With Survival Time in Sporadic Creutzfeldt-Jakob Disease.

Staffaroni AM, Kramer AO, Casey M, Kang H, Rojas JC, Orrú CD, Caughey B, Allen IE, Kramer JH, Rosen HJ, Blennow K, Zetterberg H, Geschwind MD.

JAMA Neurol. 2019 May 6. doi: 10.1001/jamaneurol.2019.1071. [Epub ahead of print]

PMID:
31058916
33.

Relevance of the interplay between amyloid and tau for cognitive impairment in early Alzheimer's disease.

Timmers M, Tesseur I, Bogert J, Zetterberg H, Blennow K, Börjesson-Hanson A, Baquero M, Boada M, Randolph C, Tritsmans L, Van Nueten L, Engelborghs S, Streffer JR.

Neurobiol Aging. 2019 Jul;79:131-141. doi: 10.1016/j.neurobiolaging.2019.03.016. Epub 2019 Apr 1.

PMID:
31055223
34.

Correlation between plasma and CSF concentrations of kynurenine pathway metabolites in Alzheimer's disease and relationship to amyloid-β and tau.

Jacobs KR, Lim CK, Blennow K, Zetterberg H, Chatterjee P, Martins RN, Brew BJ, Guillemin GJ, Lovejoy DB.

Neurobiol Aging. 2019 Apr 1;80:11-20. doi: 10.1016/j.neurobiolaging.2019.03.015. [Epub ahead of print]

PMID:
31055163
35.

Identification of neurotoxic cross-linked amyloid-β dimers in the Alzheimer's brain.

Brinkmalm G, Hong W, Wang Z, Liu W, O'Malley TT, Sun X, Frosch MP, Selkoe DJ, Portelius E, Zetterberg H, Blennow K, Walsh DM.

Brain. 2019 May 1;142(5):1441-1457. doi: 10.1093/brain/awz066.

PMID:
31032851
36.

Differential effects of neurodegeneration biomarkers on subclinical cognitive decline.

Merluzzi AP, Vogt NM, Norton D, Jonaitis E, Clark LR, Carlsson CM, Johnson SC, Asthana S, Blennow K, Zetterberg H, Bendlin BB.

Alzheimers Dement (N Y). 2019 Apr 12;5:129-138. doi: 10.1016/j.trci.2019.02.004. eCollection 2019.

37.

Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.

Mattsson N, Cullen NC, Andreasson U, Zetterberg H, Blennow K.

JAMA Neurol. 2019 Apr 22. doi: 10.1001/jamaneurol.2019.0765. [Epub ahead of print] Erratum in: JAMA Neurol. 2019 Jun 10;:.

PMID:
31009028
38.

Searching for novel cerebrospinal fluid biomarkers of tau pathology in frontotemporal dementia: an elusive quest.

Foiani MS, Cicognola C, Ermann N, Woollacott IOC, Heller C, Heslegrave AJ, Keshavan A, Paterson RW, Ye K, Kornhuber J, Fox NC, Schott JM, Warren JD, Lewczuk P, Zetterberg H, Blennow K, Höglund K, Rohrer JD.

J Neurol Neurosurg Psychiatry. 2019 Jul;90(7):740-746. doi: 10.1136/jnnp-2018-319266. Epub 2019 Apr 13.

39.

CSF and blood biomarkers for Parkinson's disease.

Parnetti L, Gaetani L, Eusebi P, Paciotti S, Hansson O, El-Agnaf O, Mollenhauer B, Blennow K, Calabresi P.

Lancet Neurol. 2019 Jun;18(6):573-586. doi: 10.1016/S1474-4422(19)30024-9. Epub 2019 Apr 10. Review.

PMID:
30981640
40.

Dynamics of extracellular matrix proteins in cerebrospinal fluid and serum and their relation to clinical outcome in human traumatic brain injury.

Minta K, Cullen NC, Nimer FA, Thelin EP, Piehl F, Clarin M, Tullberg M, Jeppsson A, Portelius E, Zetterberg H, Blennow K, Andreasson U.

Clin Chem Lab Med. 2019 Apr 15. pii: /j/cclm.ahead-of-print/cclm-2019-0034/cclm-2019-0034.xml. doi: 10.1515/cclm-2019-0034. [Epub ahead of print]

PMID:
30980710
41.

Familial Alzheimer's disease patient-derived neurons reveal distinct mutation-specific effects on amyloid beta.

Arber C, Toombs J, Lovejoy C, Ryan NS, Paterson RW, Willumsen N, Gkanatsiou E, Portelius E, Blennow K, Heslegrave A, Schott JM, Hardy J, Lashley T, Fox NC, Zetterberg H, Wray S.

Mol Psychiatry. 2019 Apr 12. doi: 10.1038/s41380-019-0410-8. [Epub ahead of print]

PMID:
30980041
42.

Amyloid β42 and Total Tau Levels in Cerebrospinal Fluid Associate with Survival in an 85-Year-Old Population-Based Cohort Followed until Death.

Ribbe M, Kern S, Börjesson Hansson A, Östling S, Zetterberg H, Blennow K, Skoog I.

Dement Geriatr Cogn Disord. 2019;47(1-2):114-124. doi: 10.1159/000499066. Epub 2019 Apr 10.

PMID:
30970371
43.

Neurofilament light chain as a biomarker in neurological disorders.

Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg H.

J Neurol Neurosurg Psychiatry. 2019 Aug;90(8):870-881. doi: 10.1136/jnnp-2018-320106. Epub 2019 Apr 9. Review.

PMID:
30967444
44.

Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study.

Lleó A, Alcolea D, Martínez-Lage P, Scheltens P, Parnetti L, Poirier J, Simonsen AH, Verbeek MM, Rosa-Neto P, Slot RER, Tainta M, Izaguirre A, Reijs BLR, Farotti L, Tsolaki M, Vandenbergue R, Freund-Levi Y, Verhey FRJ, Clarimón J, Fortea J, Frolich L, Santana I, Molinuevo JL, Lehmann S, Visser PJ, Teunissen CE, Zetterberg H, Blennow K.

Alzheimers Dement. 2019 Jun;15(6):742-753. doi: 10.1016/j.jalz.2019.01.015. Epub 2019 Apr 6.

PMID:
30967340
45.

Cardiorespiratory Fitness Modifies Influence of Sleep Problems on Cerebrospinal Fluid Biomarkers in an At-Risk Cohort.

Law LL, Sprecher KE, Dougherty RJ, Edwards DF, Koscik RL, Gallagher CL, Carlsson CM, Zetterberg H, Blennow K, Asthana S, Sager MA, Hermann BP, Johnson SC, Cook DB, Bendlin BB, Okonkwo OC.

J Alzheimers Dis. 2019;69(1):111-121. doi: 10.3233/JAD-180291.

PMID:
30958346
46.

Sleep deprivation and plasma biomarkers for Alzheimer's disease.

Olsson M, Ärlig J, Hedner J, Blennow K, Zetterberg H.

Sleep Med. 2019 May;57:92-93. doi: 10.1016/j.sleep.2018.12.029. Epub 2019 Feb 12. No abstract available.

PMID:
30953929
47.

Mass Spectrometric Analysis of Lewy Body-Enriched α-Synuclein in Parkinson's Disease.

Bhattacharjee P, Öhrfelt A, Lashley T, Blennow K, Brinkmalm A, Zetterberg H.

J Proteome Res. 2019 May 3;18(5):2109-2120. doi: 10.1021/acs.jproteome.8b00982. Epub 2019 Apr 15.

PMID:
30943367
48.

Synthetic standard aided quantification and structural characterization of amyloid-beta glycopeptides enriched from cerebrospinal fluid of Alzheimer's disease patients.

Nilsson J, Brinkmalm G, Ramadan S, Gilborne L, Noborn F, Blennow K, Wallin A, Svensson J, Abo-Riya MA, Huang X, Larson G.

Sci Rep. 2019 Apr 2;9(1):5522. doi: 10.1038/s41598-019-41897-5.

49.

Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers.

Salvadó G, Molinuevo JL, Brugulat-Serrat A, Falcon C, Grau-Rivera O, Suárez-Calvet M, Pavia J, Niñerola-Baizán A, Perissinotti A, Lomeña F, Minguillon C, Fauria K, Zetterberg H, Blennow K, Gispert JD; Alzheimer’s Disease Neuroimaging Initiative, for the ALFA Study.

Alzheimers Res Ther. 2019 Mar 21;11(1):27. doi: 10.1186/s13195-019-0478-z.

50.

Atrial fibrillation increases the risk of dementia amongst older adults even in the absence of stroke.

Rydén L, Zettergren A, Seidu NM, Guo X, Kern S, Blennow K, Zetterberg H, Sacuiu S, Skoog I.

J Intern Med. 2019 Jul;286(1):101-110. doi: 10.1111/joim.12902. Epub 2019 Apr 22.

PMID:
30895641

Supplemental Content

Loading ...
Support Center